



# Epigenetic biomarkers as predictors and correlates of symptom improvement following psychotherapy in combat veterans with PTSD

Rachel Yehuda<sup>1,2,3\*</sup>, Nikolaos P. Daskalakis<sup>1,2,4</sup>, Frank Desarnaud<sup>1,2</sup>, Iouri Makotkine<sup>1,2</sup>, Amy L. Lehrner<sup>1,2</sup>, Erin Koch<sup>1,2</sup>, Janine D. Flory<sup>1,2</sup>, Joseph D. Buxbaum<sup>3,4,5</sup>, Michael J. Meaney<sup>6,7</sup> and Linda M. Bierer<sup>1,2</sup>

<sup>1</sup> Traumatic Stress Studies Division, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>2</sup> Mental Health Care Center, PTSD Clinical Research Program and Laboratory of Clinical Neuroendocrinology and Neurochemistry, James J. Peters Veterans Affairs Medical Center, Bronx, NY, USA

<sup>3</sup> Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>4</sup> Laboratory of Molecular Neuropsychiatry, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>5</sup> Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>6</sup> Neuroscience Division, Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada

<sup>7</sup> The Agency for Science, Technology and Research, Singapore Institute for Clinical Sciences, Singapore

## Edited by:

David M. Diamond, University of South Florida, USA

## Reviewed by:

Klaus Peter Lesch, Universitätsklinikum Würzburg, Germany

Tania L. Roth, University of Delaware, USA

## \*Correspondence:

Rachel Yehuda, Traumatic Stress Studies Division, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, James J. Peters Veterans Affairs Medical Center, 526 OOMH PTSD 116/A, 130 West Kingsbridge Road, Bronx, NY 10468, USA  
e-mail: rachel.yehuda@va.gov

Epigenetic alterations offer promise as diagnostic or prognostic markers, but it is not known whether these measures associate with, or predict, clinical state. These questions were addressed in a pilot study with combat veterans with PTSD to determine whether cytosine methylation in promoter regions of the glucocorticoid related *NR3C1* and *FKBP51* genes would predict or associate with treatment outcome. Veterans with PTSD received prolonged exposure (PE) psychotherapy, yielding responders ( $n=8$ ), defined by no longer meeting diagnostic criteria for PTSD, and non-responders ( $n=8$ ). Blood samples were obtained at pre-treatment, after 12 weeks of psychotherapy (post-treatment), and after a 3-month follow-up. Methylation was examined in DNA extracted from lymphocytes. Measures reflecting glucocorticoid receptor (GR) activity were also obtained (i.e., plasma and 24 h-urinary cortisol, plasma ACTH, lymphocyte lysozyme IC<sub>50-DEX</sub>, and plasma neuropeptide-Y). Methylation of the GR gene (*NR3C1*) exon 1F promoter assessed at pre-treatment predicted treatment outcome, but was not significantly altered in responders or non-responders at post-treatment or follow-up. In contrast, methylation of the *FKBP5* gene (*FKBP51*) exon 1 promoter region did not predict treatment response, but decreased in association with recovery. In a subset, a corresponding group difference in *FKBP5* gene expression was observed, with responders showing higher gene expression at post-treatment than non-responders. Endocrine markers were also associated with the epigenetic markers. These preliminary observations require replication and validation. However, the results support research indicating that some glucocorticoid related genes are subject to environmental regulation throughout life. Moreover, psychotherapy constitutes a form of “environmental regulation” that may alter epigenetic state. Finally, the results further suggest that different genes may be associated with prognosis and symptom state, respectively.

**Keywords: PTSD, veterans, epigenetics, methylation, promoter, glucocorticoid receptor, FK506 binding protein 5, psychotherapy**

## INTRODUCTION

Cytosine methylation of glucocorticoid related genes represents an epigenetic modification thought to underlie the developmental programming of hypothalamic-pituitary-adrenal (HPA) axis function (1). Plasticity of the epigenome appears to constitute a molecular mechanism whereby genetic predispositions may be influenced by environmental exposures resulting in sustained alterations in gene expression and protein synthesis (2–4). Epigenetic modifications of a glucocorticoid receptor (GR) gene promoter were first described in the rat as a mechanism by which variations in parent – offspring interactions influence HPA-axis and

behavioral responses to stress (5, 6). Maternal care regulates the methylation state of the GR exon 1F promoter in hippocampus, which in turn, regulates GR expression, the capacity for glucocorticoid negative feedback, and HPA-axis responses to stress (5, 7). Subsequent studies in humans showed that childhood adversity associates with higher methylation of the GR exon 1F promoter (the human ortholog of the rat exon 1F promoter sequence) lower hippocampal GR expression and increased HPA-axis responses to stress (8, 9).

Recent studies reveal additional mechanisms for the influence of childhood adversity on GR signaling and HPA-axis function.

| Report Documentation Page                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                    |                                     |                                                           | Form Approved<br>OMB No. 0704-0188                  |                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------------------------------------|-----------------------------------------------------------|-----------------------------------------------------|---------------------------------|
| Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. |                                    |                                     |                                                           |                                                     |                                 |
| 1. REPORT DATE<br><b>27 SEP 2013</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                    | 2. REPORT TYPE                      |                                                           | 3. DATES COVERED<br><b>00-00-2013 to 00-00-2013</b> |                                 |
| 4. TITLE AND SUBTITLE<br><b>Epigenetic biomarkers as predictors and correlates of symptom improvement following psychotherapy in combat veterans with PTSD</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                    |                                     |                                                           | 5a. CONTRACT NUMBER                                 |                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                    |                                     |                                                           | 5b. GRANT NUMBER                                    |                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                    |                                     |                                                           | 5c. PROGRAM ELEMENT NUMBER                          |                                 |
| 6. AUTHOR(S)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                    |                                     |                                                           | 5d. PROJECT NUMBER                                  |                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                    |                                     |                                                           | 5e. TASK NUMBER                                     |                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                    |                                     |                                                           | 5f. WORK UNIT NUMBER                                |                                 |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br><b>Mental Health Care Center, PTSD Clinical Research Program, and Laboratory of Clinical Neuroendocrinology and Neurochemistry, James J. Peters Veterans Affairs Medical Center, Bronx, NY, 10468</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                    |                                     |                                                           | 8. PERFORMING ORGANIZATION REPORT NUMBER            |                                 |
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                    |                                     |                                                           | 10. SPONSOR/MONITOR'S ACRONYM(S)                    |                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                    |                                     |                                                           | 11. SPONSOR/MONITOR'S REPORT NUMBER(S)              |                                 |
| 12. DISTRIBUTION/AVAILABILITY STATEMENT<br><b>Approved for public release; distribution unlimited</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                    |                                     |                                                           |                                                     |                                 |
| 13. SUPPLEMENTARY NOTES<br><b>Frontiers in Psychiatry, Molecular Psychiatry, September 2013, Volume 4</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                    |                                     |                                                           |                                                     |                                 |
| 14. ABSTRACT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                    |                                     |                                                           |                                                     |                                 |
| 15. SUBJECT TERMS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                    |                                     |                                                           |                                                     |                                 |
| 16. SECURITY CLASSIFICATION OF:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                    |                                     | 17. LIMITATION OF ABSTRACT<br><b>Same as Report (SAR)</b> | 18. NUMBER OF PAGES<br><b>15</b>                    | 19a. NAME OF RESPONSIBLE PERSON |
| a. REPORT<br><b>unclassified</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | b. ABSTRACT<br><b>unclassified</b> | c. THIS PAGE<br><b>unclassified</b> |                                                           |                                                     |                                 |

FK506 binding protein 5 (FKBP5) regulates intracellular GR signaling by decreasing ligand binding and restricting GR translocation to the nucleus (10, 11). GR activation induces *FKBP5* (the FKBP5 gene) transcription, thus establishing an intracellular feedback loop that moderates GR sensitivity (12). FKBP5 genetic variants in interaction with childhood adversity predict the risk for affective disorders, including major depression, suicide attempts, and PTSD (13–16). Moreover, the methylation state of selected CpGs across the *FKBP5* gene is determined by an interaction between sequence-polymorphism and childhood adversity, and modulates sensitivity of FKBP5 to GR regulation (17). Various aspects of the GR (*NR3C1*) and FKBP5 genes, including genotype and gene expression, have been implicated in PTSD (12, 13, 15, 18–27). Low FKBP5 gene expression in PTSD has been associated with low plasma cortisol and PTSD severity (21, 24). Taken together, these findings suggest that childhood adversity influences the epigenetic state and transcriptional activity of genes that regulate HPA-axis responses to stress.

Importantly, stress reactivity predicts the risk for multiple affective disorders, as well as PTSD (28). Early adverse experiences are risk factors for PTSD following adult trauma exposures (29–31); thus the associated epigenetic states may represent a molecular mechanism responsible for altering subsequent responses to environmental adversity (4, 32). Neuroendocrine studies reveal that the development of PTSD following trauma exposure is associated with pre-traumatic biological markers that reflect prior sensitization to stress (33). Relatively stable changes in methylation potentially explain the chronicity and tenacity of symptoms observed in PTSD. In PTSD there is neither a complete restoration of baseline hormone levels following trauma, nor do persons with this condition feel that they have returned to a pre-trauma psychological state. PTSD is a condition that has been associated with low glucocorticoid levels, enhanced GR sensitivity, and insufficient glucocorticoid signaling (34–37). Epigenetic signals associated with childhood adversity offer a potential explanation both for why stress responses do not abate once an immediate threat is no longer present, as in the case of PTSD, and for the fact that some persons are at greater risk than others for the development of PTSD (32, 38). In fact, many of the alterations noted in PTSD have been demonstrated in association with early adversity regardless of the subsequent development of PTSD in adults (9, 17, 39, 40). On the other hand, persons who develop PTSD can also recover from this condition either spontaneously or in response to treatment (41). Moreover, an emerging trajectory in PTSD is one in which there are fluctuating symptoms, which maybe mediated by external post-traumatic environmental circumstances. This raises the possibility that some epigenetic changes, originally induced by the environment, change over time in response to subsequent challenges.

The goal of the current study was to examine methylation of the GR and FKBP5 genes – and associated downstream neuroendocrine measures, cortisol, and NPY, before and after prolonged exposure (PE) psychotherapy in veterans with PTSD. The exon 1F promoter was selected as the most biologically relevant GR promoter region for methylation analysis because this region corresponds to exon 1<sub>7</sub> of the rat GR gene, shown to be differentially methylated in the rat hippocampus based on variations in

maternal care (5), and in human peripheral blood and hippocampal post-mortem tissue in association with child abuse (9, 39, 40). We hypothesized that higher GR exon 1F promoter methylation would predict treatment response and “normalization” of PTSD related biology at post-treatment time-points but would not itself change appreciably over time. We also examined the FKBP5 exon 1 promoter methylation and, based on previously observed changes in FKBP5 gene expression in association with PTSD symptom severity (24), we hypothesized that *FKBP5* promoter methylation would change in responders, in association with glucocorticoid related measures.

The examination of biological measures in association with PTSD symptom change following an efficacious psychotherapy trial was designed to yield a sample with a variable degree of symptom improvement, with some showing large decreases in symptom severity, and others, minimal or moderate change. An additional advantage of this approach is the ability to modify symptoms without introducing exogenous medications that might have direct effects on the biological measures of interest. The participants for this study were drawn from a larger pool of combat veterans that were examined as part of an effort to identify neuroendocrine markers (e.g., cortisol, NPY) that would distinguish diagnostic, state related, and recovery markers in combat veterans randomized to PE or a minimal attention (MA) condition. To accomplish the larger objective, combat veterans were assessed for blood and urinary biomarkers prior to, and after completing, 12 weeks of treatment – either PE or MA – and after a 3-month naturalistic follow-up (for those who received PE). The direct manipulation of target symptoms with psychotherapy within a relatively short period of time (weeks to months) permits identification of biomarkers associated with relatively rapid symptom change and treatment-associated recovery. Assessment prior to and following psychotherapy allows differentiation of prognostic indicators from state markers of symptom change. Markers that do not change as symptoms improve may be prognostic indicators or reflect measures associated with risk for PTSD. Previous results from a preliminary study of combat veterans demonstrated that GR responsiveness predicted treatment outcome (42). Because it was of interest to draw specific conclusions about symptom change in association with a structured psychotherapy, in this report we only include participants in the active arm (i.e., who received and completed PE) who completed the pre-treatment, post-treatment, and follow-up assessments.

## MATERIALS AND METHODS

### PARTICIPANTS

This report represents a subsample ( $n = 16$ ) of a larger study of 113 combat veterans who enrolled in a clinical trial comparing the effects of PE to a MA condition, conducted at the James J. Peters Bronx VA Medical Center (JJP BVAMC). Results of the subset of completers will be reported elsewhere. The current subsample comprised 14 men and 2 women who completed PE treatment. Nine were Vietnam veterans, and seven had recently returned from active duty in Iraq or Afghanistan. The decision to study PE completers in this subset was based on two considerations. First, following MA, the participants were allowed to begin active psychotherapy. For this reason, the initial study did not have a

follow-up evaluation for those receiving MA. Second, by comparing participants who received the same intervention, biological correlates of symptom severity are not confounded with effects of treatment type.

As the molecular measures reported here were not part of the original protocol, selection of this subgroup was based on (1) having agreed to the future use of their biological samples; (2) having completed all three evaluations (pre-treatment, post-treatment, and follow-up); (3) having participated in the PE condition; and (4) having sufficient remaining sample for the analysis of promoter methylation of GR and FKBP5 genes after other study measures had been obtained. Participants in this subsample were not appreciably different from those who completed PE in the parent study with respect to pre-treatment demographic or clinical variables, or post-treatment measures. All procedures were approved by the IRB at the JJP BVAMC, all participants signed written, informed consent prior to initiation of study procedures.

### **Inclusion/exclusion criteria**

Following a comprehensive medical (including lab testing) and psychological evaluation, participants were excluded if they did not experience a Criterion A traumatic event during military service or meet DSM-IV criteria for current PTSD with a duration of at least 6 months. Additional exclusion criteria included having significant illness that would interfere with interpretation of biological data, such as insulin-dependent diabetes, seizure disorder, or any disease requiring ongoing treatment with systemic steroids; regular use of benzodiazepines or oral steroids; a BMI >40; smoking more than two packs per day; meeting criteria for substance abuse or dependence within the last 6 months; a lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, obsessive compulsive disorder, or being in any acute clinical state that necessitated prompt initiation of pharmacotherapy or other treatment, including assessed suicide risk. Veterans receiving psychotropic medications for PTSD were eligible to participate if they had maintained a stabilized therapeutic dose for a minimum of 2 months prior to randomization.

### **PROCEDURE**

A comprehensive psychological evaluation was performed by a clinical psychologist at the three study time-points (pre- and post-treatment, follow-up). Several structured diagnostic instruments were used including the Structured Clinical Interview for DSM-IV (SCID) (43), and the Clinician Administered PTSD Scale (CAPS) (44). The CAPS additionally provided a continuous measure of symptom severity of PTSD. The PTSD Symptom Scale – Self-Report Version (PSS-SR) was used as a self-report of PTSD symptoms (45). Two self-report measures were administered to assess childhood trauma and life events. The Childhood Trauma Questionnaire (CTQ) was used to assess early trauma (46), and the Deployment Risk and Resiliency Inventory (DRRI) to assess military and civilian life events pre- and post-deployment (47). For all subjects, an independent evaluator (i.e., not the individual who provided treatment) assessed clinical outcome following treatment.

### **Biological measures**

The primary molecular measures included GR- and FKBP5-promoter methylation. These were obtained in parallel with the psychological assessments. We also examined FKBP5 gene expression in subjects for whom there was sufficient sample. A battery of HPA-axis markers was examined as part of the parent study to assess basal cortisol levels and GR responsiveness. Reported here are the biological measures that should be functionally related to the molecular measures and/or may vary in response to symptom change. These include basal plasma cortisol, 24 h-urinary cortisol levels, plasma ACTH, and cortisol responses to a low dose (0.50 mg) dexamethasone suppression test (DST), glucocorticoid sensitivity as assessed by the lymphocyte lysozyme IC<sub>50</sub>-DEX, and plasma NPY.

### **Sample processing and hormone determination**



Blood samples pre- and post-dexamethasone were collected as previously described (48). Plasma was extracted from EDTA containing tubes, aliquoted, and frozen at –80°C until subsequent hormonal analysis. Urine samples were collected over a 24-h period as previously described (49). Cortisol (plasma and urinary), dexamethasone, and NPY were determined by radioimmunoassay as previously described (48, 50). Plasma ACTH was determined using an enzyme-linked immunosorbent assay (ELISA; ALPCO Diagnostics, Salem, NH, USA). The intra- and inter-assay coefficients of variation were 4.7 and 7.1% for ACTH, 2.3 and 6.1% for cortisol, 8.0 and 9.0% for dexamethasone, and 3.5 and 11.6% for NPY, respectively.

### **Peripheral blood mononuclear cells isolation**

Peripheral blood mononuclear cells (PBMCs) were purified from basal EDTA pretreated blood by Ficoll-Paque (Amersham, UK) using Accuspin tubes (Sigma-Aldrich, Saint Louis, MO, USA). After two washes in Hanks' Balanced Salt Solution (Life Technologies, Grand Island, NY, USA), PBMCs were counted with a hemocytometer. Some cell pellets were immediately used for determination of lysozyme IC<sub>50</sub>-DEX as previously described (51). Some cell pellets were quickly frozen, stored at –80°C, and later used for DNA extraction (see below) and a portion of cell pellets was dissolved in TRIzol Reagent (Invitrogen, CA, USA) by adding 1 ml of the reagent per  $1 \times 10^7$  cells, quickly frozen, stored at –80°C, and later used for RNA extraction (see below).

### **DNA cytosine methylation sodium bisulfite mapping**

Genomic DNA was extracted from frozen PBMC pellets following the Flexigene DNA kit protocol (Qiagen, Valencia, CA, USA). Methylation mapping of the human GR exon 1F promoter (**Figure 1A**) was performed following Dr. Meaney's laboratory recommendations and as previously described for human hippocampus (9). The methylation mapping method for the human FKBP5 proximal promoter located upstream of exon 1 (**Figure 1B**) was developed in Dr. Yehuda's laboratory. Sodium bisulfite treatment was carried out according to the EpiTect Bisulfite kit protocol (Qiagen, Valencia, CA, USA). In each sodium bisulfite conversion reaction, 0.8 µg of genomic DNA was used. In the same experiment, 0.8 µg of Universal Methylated Standard (Zymo Research, Irvine, CA, USA) was treated

**A NR3C1****B FKBP51**

**FIGURE 1 | Schematic representation of human NR3C1 and FKBP51 exon 1 promoter regions analyzed by DNA cytosine methylation bisulfite mapping.** In both panels the solid black line boxes with a number represent the different exons and the 5'–3' orientation goes from left to right. **(A)** The NR3C1 gene 5' region is composed of multiple first exons and the translation start site is located within exon 2. The

numbering of exon 1F promoter is based on the translational start site (+1). The CpG sites that have been analyzed by bisulfite sequencing are in red and numbered. **(B)** The FKBP51 gene proximal promoter region is numbered based on the transcriptional start site (+1) of exon 1. The CpG sites that have been analyzed by bisulfite sequencing are in red and numbered.

with sodium bisulfite to check completion of the sodium bisulfite reaction. The genomic region of the human GR exon 1F promoter was subjected to PCR amplification using the following primer sequences: 5'-GTG GTG GGGGAT TTG-3'

(forward); 5'-ACCTAATCTCTCTAAAAC-3' (reverse) following previously published procedures (9). The thermocycler protocol involved an initial denaturation (5 min, 95°C), 35 cycles of denaturation (1 min, 95°C), annealing (2 min 30 s, 55°C),

and extension (1 min, 72°C), and then a final extension (5 min, 72°C) with subsequent cooling at 4°C. The resulting PCR product was subjected to another round of PCR, using the following nested primers: 5'-TTTTTGAAGTTTTTTAGAGGG-3' (forward); 5'-AATTTCTCCAATTTCTTTCTC-3' (reverse). The thermocycler protocol was the same as the initial PCR procedure except that the extension step was prolonged to 10 min. The genomic region of the human FKBP5 exon 1 promoter was subjected to PCR amplification using the following primer sequences: 5'-GGTAGGTTTTGTGGATAGATAGGA-3' (forward); 5'-ACTCCGCTAACCTTCAAC-3' (reverse). The thermocycler protocol involved an initial denaturation (4 min, 95°C), 35 cycles of denaturation (30 s, 95°C), annealing (30 s, 45°C), and extension (1 min, 72°C), and then a final extension (10 min, 72°C) with subsequent cooling at 4°C. The resulting PCR product was subjected to another round of PCR, using the following nested primers: 5'-AGGGGGTGTAGTTTTTATTATTTTTT-3' (forward); 5'-ACTCCGCTAACCTTCAAC-3' (reverse). The thermocycler protocol was the same as the initial PCR procedure. The resulting PCR products were analyzed on a 2% agarose gel and then purified using QIAquick PCR purification kit (Qiagen, Valencia, CA, USA). The PCR products were subcloned using a PCR product cloning kit (Qiagen) and individual plasmid containing the ligated promoter regions were extracted and sequenced (Genewiz, Inc., South Plainfield, NJ, USA). The sequences for 20 individual clones were aligned and analyzed in the DNA Alignment software program BioEdit (Ibis Biosciences, Carlsbad, CA, USA). The DNA samples were analyzed in batches of 20–30 samples. Variability in the DNA bisulfite treatment did not exceed 2% between the batches.

### Gene expression

RNA, from Trizol-dissolved PBMCs, was extracted using commercially available kits (RNeasy Mini Kit and RNeasy MinElute Cleanup Kit, Qiagen). Extracted RNA was evaluated for its quality using NanoDrop 2000 Spectrophotometer (Thermo Scientific). RNA was aliquoted and stored at  $-80^{\circ}\text{C}$  until use.

For GR exon 1F expression, cDNA synthesis was completed using Maxima reverse transcriptase (Thermoscientific) and GR target oligo (CAG GGG TGC AGA GTT CGA TG) since GR expression levels are very low in blood cells. Quantitative real-time PCR was performed with a LightCycler 480 (Roche Applied Science). *NR3C1* exon 1F primers (forward primer 5'-AAG AAA CTG GAG AAA CTC GGT GGC-3', reverse primer 5'-TGA GGG TGA AGA CGC AGA AAC CTT-3') and RT<sup>2</sup> PCR primer sets for two endogenous reference genes ( $\beta 2$  microglobulin, Catalog no. PPH01094E; SABiosciences and glyceraldehyde-3-phosphate dehydrogenase, Cat#PPH14985F, Sabioscience) were used. Only one cDNA was amplified in each PCR (monoplex).

For FKBP5 expression, cDNA was synthesized by reverse transcription reaction using High capacity cDNA Archive Kit (Applied Biosystems). Real-time PCR was performed using an ABI Step One Plus Real-Time PCR Instrument (Applied Biosystems) and TaqMan probes (Applied Biosystems). The primers used to target exon junctions 7–8 and 8–9 of the *FKBP51* gene, and four endogenous reference genes, have been previously described (21). Only one cDNA was amplified in each PCR (monoplex).

The reactions were run in triplicate for each sample and were quantitated by selecting the amplification cycle when the PCR product of interest was first detected (threshold cycle,  $C_t$ ). To account for the differences in the amounts of input material across samples, the expression level of each transcript in each sample was normalized to the geometric mean of the expression levels of the endogenous reference genes using the  $2^{-\Delta\Delta C_t}$  method.

### STATISTICAL ANALYSIS

Responder status was defined by the presence or absence of PTSD at post-treatment evaluation, as determined by an independent psychologist using the CAPS for DSM-IV. For GR and FKBP5, number of methylated sites in the CpG region examined for each subject was calculated by observing the percentage of methylated clones at each site and then totaling the number of sites with percentages greater than zero. Because the number of individual sites examined was 39 for GR and 38 for FKBP5, the potential range of number of methylated sites for GR is 0–39, with an actual range of 1–16; the potential range for FKBP5 is 0–38, with an actual range of 2–20. An alternative measure for promoter methylation was the sum % methylation. For this measure, at each site of the promoter region, the total number of methylated clones (out of 30) was converted to a percentage. The percentages across all sites were then added to create a total summed percentage of methylation.

Measures of central tendency and variability (mean and SE) were calculated at baseline, treatment completion, and follow-up for all continuous primary and secondary clinical outcome measures and biological variables. Baseline comparisons of group differences were conducted using independent samples *t*-tests for continuous variables and chi-square analysis for categorical variables. Correlation analyses were conducted to determine appropriate covariates for repeated measures analysis. Repeated measures ANOVAs and ANCOVAs were conducted using responders and non-responders to explore within and between group changes on biological and psychological measures in order to determine predictors and correlates of treatment outcome. Additional bivariate correlations were used to measure association of GR- and FKBP5-promoter methylation at pre-treatment with clinical and other biological variables at post-treatment or follow-up and of post-treatment variables with those at follow-up. For the correlational analysis, the number of methylated sites was selected as the most sensitive measure of methylation in this study. Statistical significance for all analyses was set at  $p < 0.05$ .

## RESULTS

### DEMOGRAPHIC, DESCRIPTIVE, AND CLINICAL MEASURES

**Table 1** reports comparisons of the responder and non-responder groups at baseline on a variety of demographic and descriptive characteristics. There were significant group differences in age indicating that responders tended to be younger, had PTSD for a shorter duration, and had fewer total lifetime traumatic events, than non-responders. A chi-square analysis of the number of veterans in the two conflicts in relation to responder status did not reach statistical significance in this small sample. Moreover, initial PTSD symptom severity was comparable for responders and non-responders, as assessed by clinician or self-report (**Table 2**).

**Table 1 | Baseline characteristics comparing responders to non-responders.**

|                                                   | <b>Responders<br/>(<i>n</i> = 8)<br/>M (SD) or %</b> | <b>Non-responders<br/>(<i>n</i> = 8)<br/>M (SD) or %</b> |                        |                         |
|---------------------------------------------------|------------------------------------------------------|----------------------------------------------------------|------------------------|-------------------------|
| Age                                               | 41.25 (17.82)                                        | 57.88 (7.45)                                             | $t_{(9,4)}^d = -2.435$ | <b><i>p</i> = 0.037</b> |
| Years of education                                | 13.38 (2.20)                                         | 15.50 (2.39)                                             | $t_{(14)} = -1.850$    | ns                      |
| Marital status                                    | Single (37.5%)                                       | Single (37.5%)                                           | $\chi^2_{(1)} = 1.000$ | ns                      |
|                                                   | Married or living with partner (62.5%)               | Married or living with partner (62.5%)                   |                        |                         |
| Ethnicity                                         | Hispanic (37.5%)                                     | Hispanic (50%)                                           | $\chi^2_{(2)} = 0.476$ | ns                      |
|                                                   | Black (37.5%)                                        | Black (37.5%)                                            |                        |                         |
|                                                   | White (25%)                                          | White (12.5%)                                            |                        |                         |
| Conflict                                          | OEF/OIF (62.5%)                                      | OEF/OIF (25%)                                            | $\chi^2_{(1)} = 2.286$ | ns                      |
|                                                   | Vietnam (37.5%)                                      | Vietnam (75%)                                            |                        |                         |
| Stabilized on psychotropics                       | Yes (62.5%)                                          | Yes (62.5%)                                              | $\chi^2_{(1)} = 1.000$ | ns                      |
| Lifetime CAPS <sup>a</sup> total score            | 92.75 (12.70)                                        | 105.25 (15.15)                                           | $t_{(14)} = -1.789$    | ns                      |
| CTQ <sup>b</sup> total                            | 9.43 (3.72)                                          | 10.81 (4.02)                                             | $t_{(14)} = -0.717$    | ns                      |
| Time since first DRRI <sup>c</sup> trauma (years) | 25.00 (17.85)                                        | 45.00 (8.83)                                             | $t_{(10,2)}^d = 2.841$ | <b><i>p</i> = 0.017</b> |
| DRRI pre-deployment life events                   | 4.50 (3.16)                                          | 7.25 (3.15)                                              | $t_{(14)} = -1.742$    | ns                      |
| DRRI post-deployment life events                  | 5.13 (3.68)                                          | 10.38 (2.56)                                             | $t_{(14)} = -3.312$    | <b><i>p</i> = 0.005</b> |
| DRRI total life events                            | 9.63 (5.80)                                          | 17.63 (3.16)                                             | $t_{(14)} = -3.424$    | <b><i>p</i> = 0.004</b> |

<sup>a</sup>Clinician Administered PTSD Scale;<sup>b</sup>Childhood Trauma Questionnaire;<sup>c</sup>Deployment Risk and Resilience Inventory;<sup>d</sup>unequal variance t-test.**Table 2 | Interview and self-report measures at before and after treatment and at 12-week follow-up in Responders (R) and Non-responders (NR).**

|                                       | <b>Pre-treatment</b> |              | <b>Post-treatment</b> |              | <b>Follow-up</b> |              | <b><i>p</i>-Value</b> |              |              |
|---------------------------------------|----------------------|--------------|-----------------------|--------------|------------------|--------------|-----------------------|--------------|--------------|
|                                       | <b>R</b>             | <b>NR</b>    | <b>R</b>              | <b>NR</b>    | <b>R</b>         | <b>NR</b>    | <b>Group</b>          | <b>Time</b>  | <b>G × T</b> |
| Current PTSD severity <sup>a</sup>    | 75.00 (6.39)         | 81.75 (6.39) | 26.50 (6.78)          | 70.50 (6.78) | 30.00 (7.72)     | 61.75 (7.72) | <b>0.004</b>          | <b>0.000</b> | <b>0.003</b> |
| Self-rated PTSD severity <sup>b</sup> | 36.50 (2.39)         | 35.17 (2.76) | 18.75 (3.98)          | 34.50 (4.60) | 14.63 (3.15)     | 32.00 (3.63) | <b>0.016</b>          | <b>0.000</b> | <b>0.004</b> |

<sup>a</sup>Clinician Administered PTSD Scale (CAPS);<sup>b</sup>PTSD Symptom Scale-Self-Report (PSS-SR).

## TREATMENT RESPONSE AND CLINICAL INDICATORS


**Table 2** also describes changes in measures of PTSD. Consistent with defining groups on the basis of their diagnostic status at post-treatment, there were significant group × time interactions for PTSD symptom severity.

## METHYLATION OF A GR PROMOTER

Levels of methylation across the GR exon 1F promoter were generally low, as expected of CpG sites lying within a CpG island. **Figure 2A** demonstrates a significant group difference in the number of CpG methylated sites across the GR exon 1F promoter between responders and non-responders at pre-treatment ( $t_{14} = 2.43$ ,  $p = 0.029$ ), with a greater average number of methylated sites in responders ( $4.5 \pm 0.6$ ) than non-responders ( $2.5 \pm 0.6$ ). A similar pre-treatment difference in GR exon 1F promoter methylation was observed when the sum % methylation measure (**Figure 2B**) was used ( $t_{14} = 2.29$ ,  $p = 0.045$ ; responders  $28.7 \pm 5.9$ , non-responders:  $13.8 \pm 2.8$ ).


In repeated measures analysis of number of methylated sites, there was a main effect of group ( $F_{1,14} = 7.584$ ,  $p = 0.016$ ) across the three time-points, but no significant effect of time ( $F_{2,28} = 2.41$ , ns) or group × time interaction ( $F_{2,28} = 0.171$ , ns). The significant group effect reflects higher level of number of methylated CpG sites in samples from responders compared to non-responders. Similar effects at a trend level of significance were observed when using the sum % methylation measure (group:  $F_{1,14} = 3.627$ ,  $p = 0.078$ , trend; time:  $F_{2,28} = 2.22$ , ns, group × time interaction:  $F_{2,28} = 0.401$ , ns).

Treatment response for individual subjects was predicted by pre-treatment GR exon 1F promoter methylation. Pre-treatment levels of GR exon 1F promoter methylation were significantly correlated with both post-treatment PTSD symptom severity (**Figure 3A**) and the change in symptom severity from pre- to post-treatment (**Figure 3B**). Higher post-treatment GR exon 1F promoter methylation also predicted lower self-reported (but not clinician-rated) PTSD symptoms at follow-up (**Figure 4**).




**FIGURE 2 | GR- and FKBP5-promoter methylation at pre-treatment, post-treatment and follow-up.** GR- (A,B) and FKBP5-promoter (C,D) methylation shown by mean  $\pm$  SE of number of methylated sites (A,C) or sum % methylation (B,D). Responders ( $n=8$ ) to treatment are represented by blue, open circles and non-responders ( $n=8$ ) by red

squares. For GR exon 1F promoter methylation, there is a significant group difference at Pre-treatment, but no main effect of time and no group by time interaction. FKBP5 promoter methylation shows a significant group by time interaction, but no main effects of group or time. Statistical significance was set at  $p < 0.05$ .



**FIGURE 3 | Relationship between GR exon 1F promoter methylation at pre-treatment and PTSD symptom severity at post-treatment.** Correlations of pre-treatment GR exon 1F promoter methylation (# of methylated sites) with post-treatment CAPS total score (A) and change in CAPS total score from pre- to post-treatment (B). Responders ( $n=8$ ) to treatment are represented by blue, open

circles and non-responders ( $n=8$ ) by red squares. The higher number of GR exon 1F promoter methylated sites at pre-treatment corresponded to a lower CAPS total score at Post-treatment and a greater reduction in symptoms from pre- to post-treatment. Correlation coefficients are denoted in the different panels. Statistical significance was set at  $p < 0.05$ .



Pre-treatment GR exon 1F promoter methylation additionally predicted several post-treatment biological measures. Pre-treatment GR exon 1F promoter methylation was positively associated with post-treatment 24 h-urinary cortisol levels (Figure 5A) and plasma NPY (Figure 5B). Although only at a trend level of significance, pre-treatment GR exon 1F promoter methylation was associated with follow-up glucocorticoid sensitivity as determined by the lymphocyte lysozyme test 3 months after treatment ended (Figure 5C). Note that lower  $IC_{50-DEX}$  indicates greater glucocorticoid sensitivity. Importantly, there were no significant correlations observed cross-sectionally between GR exon 1F promoter methylation and PTSD symptoms or other endocrine measures in this sample.

### METHYLATION OF THE FKBP5 PROMOTER

In contrast to the findings for the GR exon 1F promoter, FKBP5 promoter number of methylated sites showed variation in association with treatment outcome reflected in a significant group by time interaction effect ( $F_{2,24} = 4.576$ ,  $p = 0.021$ ). Responders showed a decrease, whereas non-responders showed an increase in FKBP5 promoter methylation over this same period (Figure 2C). This interaction effect was confirmed at a trend level of significance using the sum % methylation measure ( $F_{2,22} = 4.276$ ,  $p = 0.063$ , trend; Figure 2D) and was likely due to decreased levels of FKBP5 promoter methylation among responders from post-treatment to the follow-up time-point.

In contrast to GR exon 1F promoter methylation, for which measures at pre-treatment predicted symptoms or biological measures at subsequent time-points, FKBP5 promoter methylation tended to associate cross-sectionally with biological measures at pre- and post-treatment time-points. For example, FKBP5

promoter methylation at pre-treatment was significantly correlated with plasma cortisol levels (Figure 6A) such that higher FKBP5 promoter methylation was correlated with lower cortisol levels at pre-treatment, a result compatible with our previous findings of lower FKBP5 gene expression in PTSD (21). Following treatment, FKBP5 promoter methylation was significantly negatively correlated with pituitary response to dexamethasone as measured by ACTH levels following the administration of low dose dexamethasone (Figure 6B). A similar correlation was observed at a trend level of significance with post-dexamethasone cortisol ( $r = -0.509$ ,  $n = 15$ ,  $p = 0.053$ ). Since lower ACTH or cortisol levels following the low dose DST reflect a greater negative-feedback inhibition of the HPA-axis, these findings suggest that greater GR responsiveness associated with higher levels of FKBP5 promoter methylation.



Levels of FKBP5 promoter methylation at follow-up were also associated with measures of both endocrine function and symptoms at post-treatment (Figure 7). Thus, FKBP5 promoter methylation at follow-up was significantly correlated with both plasma cortisol and 24 h-urinary cortisol at post-treatment (Figures 7A,B, respectively), suggesting that FKBP5 promoter methylation may be associated with changes in HPA-axis activity, in association with changes in symptom expression, rather than reflecting upstream regulation of cortisol. The finding that post-treatment PTSD severity was correlated with FKBP5 promoter methylation at follow-up (Figure 7C) is consistent with this idea.

### EXPRESSION OF GR EXON 1F AND FKBP5

Because the assays for gene expression were not planned at the outset of this clinical trial, biological material was only available at the follow-up time-point and not for all subjects. Treatment responders showed higher expression of the GR exon 1F and FKBP5 genes compared with non-responders (for GR exon 1F:  $1.0 \pm 0.1$  and  $0.4 \pm 0.1$ , respectively, for FKBP5 exon 8/9:  $3.1 \pm 1.4$  and  $1.2 \pm 0.4$ , respectively). This difference was significant only for GR exon 1F ( $t_4 = 2.29$ ,  $p = 0.019$ ) in this small sample.

Plasma cortisol was positively correlated with FKBP5 gene expression (for exon 7/8 transcript:  $r = 0.654$ ,  $n = 10$ ,  $p = 0.040$ ) and negatively correlated with GR exon 1F expression ( $r = -0.853$ ,  $n = 6$ ,  $p = 0.031$ ) at follow-up. FKBP5 gene expression also negatively correlated with the decline in cortisol in response to dexamethasone (for the exon 7/8 transcript:  $r = -0.869$ ,  $n = 10$ ,  $p = 0.002$ ).

Endocrine markers assessed at pre- and post-treatment correlated with FKBP5 gene expression at follow-up. For example, ACTH levels following dexamethasone at pre- and post-treatment predicted lower GR exon 1F, and higher FKBP5 gene expression at the 7/8 transcript (at pre-treatment,  $r = -0.929$ ,  $n = 6$ ,  $p = 0.022$  for GR exon 1F and  $r = 0.712$ ,  $n = 9$ ,  $p = 0.031$  for the FKBP5 exon 7/8 transcript; at post-treatment  $r = -0.616$ ,  $n = 6$ , ns for GR exon 1F and  $r = 0.768$ ,  $n = 10$ ,  $p = 0.016$  for the FKBP5 exon 8/9 transcript). This suggests that those showing relatively lower pituitary GR responsiveness before and/or after treatment were most likely to demonstrate a treatment (or symptom) induced decrease in GR gene expression and/or increase in FKBP5 gene expression, a likely consequence of demethylation of the FKBP5 promoter region described above.



### METHYLATION AND TRAUMATIC LIFE EVENTS



There was a significant difference in total life events in responders vs. non-responders (Table 1). GR exon 1F promoter methylation at pre-treatment was significantly associated with time since the first reported trauma, and at post-treatment with DRRI total life events (Figures 8A,B, respectively). There was no relationship between FKBP5 promoter methylation (at any time-point) with either the total number of negative life events or time since initial trauma.

Interestingly, DRRI total life events predicted PTSD symptom severity assessed by CAPS at post-treatment ( $r = 0.690$ ,  $n = 16$ ,

$p = 0.003$ ). The three associations did not appreciably change when controlling for participant age at the time of the GR exon 1F promoter methylation assessment.

### DISCUSSION

This is the first report in the literature to investigate cytosine methylation changes in association with changes in psychiatric symptoms and neuroendocrine measures in response to psychotherapy. In this small sample of responders and non-responders to PE psychotherapy, pre-treatment GR exon 1F



promoter methylation predicted treatment outcome, but was not significantly altered in either group at post-treatment or follow-up. In contrast, pre-treatment cytosine methylation of the FKBP5 promoter did not predict treatment response, but decreased in association with recovery in veterans who no longer met diagnostic criteria for PTSD after psychotherapy. These findings distinguish two seemingly stable epigenetic markers that may associate, respectively, with prognosis (GR gene methylation) and symptom severity (FKBP5 gene methylation).

The focus in this study on the GR gene was based on observations that implicate enhanced GR sensitivity in PTSD (36). The focus on FKBP5, a co-chaperone of the GR cellular complex, is

based on studies showing that FKBP5 inhibits the nuclear translocation of ligand-bound GR, thereby directly affecting functional GR sensitivity (12). FKBP5 gene expression is up-regulated by glucocorticoids through consensus glucocorticoid response elements (GREs) and by glucocorticoid-induced demethylation of the gene (12, 17, 52, 53). The underlying epigenetic mechanisms involved in the interaction of these two genes are not fully known, and remain of great interest. The findings of this study demonstrate distinct correlates with respect to PTSD for these two glucocorticoid related genes.

The lack of change over time in GR gene methylation is consistent with the idea that imprinting by early environmental

experiences may result in enduring epigenetic changes in expression of this gene (1, 54). In animals, changes in GR gene methylation related to variations in maternal care are enduring, predicting GR responsiveness under a variety of experimental challenges in adulthood (5, 7, 55). Similarly, child maltreatment associates with hypermethylation of the GR exon 1F promoter in both post-mortem hippocampus (9) and leukocytes and an attenuated cortisol response to the Dex/CRH test in healthy adults (40). Our findings are consistent with the idea that environmental influences on the methylation of the GR exon 1F promoter are stable into adulthood and associated with clinical outcomes. Thus, methylation of this GR promoter was relatively stable across a 6-month period during which three independent measures were obtained under circumstances of changing symptom severity. This conclusion is buttressed by the strong inverse correlation between total number of negative life events as measured by the DRR and GR gene 1F promoter methylation, as well as by the negative relationship between GR gene methylation and duration since initial trauma exposure. To our knowledge this finding is the first systematic documentation in humans of the stability of an epigenetic mark associated with childhood experience. In contrast, studies with rodents have been limited in most studies to a single assessment, typically in selected brain regions.


Variations in maternal care regulate hippocampal GR promoter methylation that, in turn, determines hippocampal GR expression, the efficiency of glucocorticoid negative-feedback regulation of hypothalamic CRF expression, and the magnitude of HPA-axis responses to stress (5, 56, 57). GR promoter methylation is thus an upstream regulator of GR gene expression and HPA-axis responsiveness. In this study, GR promoter methylation at pre-treatment predicted HPA-axis activity following psychotherapy, but was not correlated with baseline cortisol measures at pre-treatment. Likewise in a recent cross-sectional study (40), GR promoter methylation in human lymphocytes did correlate with the cortisol response to the DEX/CRH challenge in a sample of healthy adults, many of whom had reported child abuse, but apparently not with basal measures of cortisol. It is possible, that cross-sectional correlations would have been observed herein following a corresponding level of HPA-axis manipulation as implicated by the DEX/CRF challenge. Nonetheless, the associations between GR exon 1F promoter methylation and numerous functional glucocorticoid measures further increase confidence in the validity of the former to inform downstream processes related to functional neuroendocrine outcomes, but these associations may not necessarily be present when examined cross-sectionally.

Unlike GR promoter methylation, FKBP5 promoter methylation did not predict treatment response, but was correlated with measures of cortisol and glucocorticoid sensitivity. These findings are consistent with the role of FKBP5 as a moderator of intracellular GR signaling. These results are also consistent with our previous findings of an association between FKBP5 gene expression and plasma cortisol levels in WTC trauma survivors (21). The FKBP5 site in the current study differs from that examined by Klengel et al. (17), which associates with childhood adversity. This group examined regions (intronic regions and distal promoter region) of the FKBP5 gene that contain GREs. Methylation status in the intronic regions, especially of intron 7, mediated the

effects of early life adversity on adult stress sensitivity since an association of child abuse with FKBP5 methylation at intron 7 has been reported, depending on FKBP5 genotype (17). Interestingly, methylation at these respective intronic regions in the rat, which also contain GREs, were decreased after a month of corticosterone administration resulting in an increase in FKBP5 gene expression strengthening the link between glucocorticoid levels and FKBP5 gene expression through epigenetic mechanisms that can also operate later in life (52, 53). Our choice of examining the proximal promoter region was prompted by the notion that methylation of this region would influence FKBP5 gene expression. Consistent with the findings of Klengel et al. (17), we found that increased levels of cortisol associated with decreased levels of FKBP5 promoter methylation.

These findings permit a distinction between biological markers associated with prognosis and treatment outcome. Thus, GR promoter methylation at pre-treatment was associated with treatment response, while dynamic variation in FKBP5 promoter methylation associated with treatment outcome. A model for understanding the unique relationships observed in GR and FKBP5 methylation and their potential interactions in PTSD is presented in **Figure 9**. Early experience may influence both GR and FKBP5 gene methylation. In PTSD, GR sensitivity is increased, likely resulting from reduced GR promoter methylation, which would ultimately result in lowered cortisol levels and, therefore, low glucocorticoid signaling. The low cortisol levels would serve to further decrease FKBP5 gene expression through an intracellular loop mediated by GREs in the FKBP5 gene. Decreased FKBP5 gene expression could serve to sustain an increased GR sensitivity. A decline in FKBP5 promoter methylation, such as occurred in treatment responders, might allow for an increase in FKBP5 gene expression, which would, in turn, ultimately decrease GR sensitivity. Thus, we found that treatment responders showed decreased FKBP5 promoter methylation, suggestive of increased FKBP5 gene expression, and measures of HPA-axis activity (i.e., plasma and urinary cortisol levels) reflecting decreased GR sensitivity. Likewise, higher levels of GR promoter methylation, suggestive of lower GR expression, were also associated with a positive response to treatment. Our previous studies suggest that increased GR sensitivity is a hallmark of PTSD (36). The mechanisms by which such dynamic changes in GR sensitivity associate with changes in PTSD symptoms remains to be fully elucidated; however the current findings suggest that the molecular mechanisms that regulate glucocorticoid signaling associate with treatment outcome.

In sum, this is the first demonstration of an epigenetic alteration in association with treatment response. This study represents an important initial step in establishing relevant molecular markers for PTSD therapies. In particular, the longitudinal approach in which symptoms vary over time is essential to distinguishing PTSD predictors from symptom correlates, and permits a more rational evaluation of potential treatment targets. The preliminary observations presented here require replication. Future prospective studies could detect the level of functional significance of small differences in methylation at baseline (as was the case for the GR-1F promoter) or small changes in methylation after an environmental challenge (as was noted for FKBP5 promoter



methylation). However, the results support recent research indicating that some glucocorticoid related genes may be subject to environmental regulation throughout life (58). Moreover, the data suggest that psychotherapy resulting in substantial symptom change constitutes a form of “environmental regulation” that may alter epigenetic state. Finally, the results demonstrate that different genes may be associated with prognosis and symptom state, respectively.

## REFERENCES

- Kappeler L, Meaney MJ. Epigenetics and parental effects. *Bioessays* (2010) 32:818–27. doi:10.1002/bies.201000015
- Zhang TY, Meaney MJ. Epigenetics and the environmental regulation of the genome and its function. *Annu Rev Psychol* (2010) 61(439–466):C431–3. doi:10.1146/annurev.psych.60.110707.163625
- Klengel T, Binder EB. Allele-specific epigenetic modification: a molecular mechanism for gene-environment interactions in stress-related psychiatric disorders? *Epigenomics* (2013) 5:109–12. doi:10.2217/epi.13.11
- Szyf M. How do environments talk to genes? *Nat Neurosci* (2013) 16:2–4. doi:10.1038/nn.3286
- Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. *Nat Neurosci* (2004) 7:847–54. doi:10.1038/nn1276
- Suderman M, McGowan PO, Sasaki A, Huang TC, Hallett MT, Meaney MJ, et al. Conserved epigenetic sensitivity to early life experience in the rat and human hippocampus. *Proc Natl Acad Sci U S A* (2012) 109(Suppl 2):17266–72. doi:10.1073/pnas.1121260109
- Liu D, Diorio J, Tannenbaum B, Caldji C, Francis D, Freedman A, et al. Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. *Science* (1997) 277:1659–62. doi:10.1126/science.277.5332.1659
- Heim C, Newport DJ, Heit S, Graham YP, Wilcox M, Bonsall R, et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. *JAMA* (2000) 284:592–7. doi:10.1001/jama.284.5.592

9. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nat Neurosci* (2009) **12**:342–8. doi:10.1038/nn.2270
10. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. *Endocr Rev* (1997) **18**:306–60. doi:10.1210/er.18.3.306
11. Stechschulte LA, Sanchez ER. FKBP51-a selective modulator of glucocorticoid and androgen sensitivity. *Curr Opin Pharmacol* (2011) **11**:332–7. doi:10.1016/j.coph.2011.04.012
12. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. *Psychoneuroendocrinology* (2009) **34**(Suppl 1): S186–95. doi:10.1016/j.psyneuen.2009.05.021
13. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. *JAMA* (2008) **299**:1291–305. doi:10.1001/jama.299.11.1291
14. Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch MA. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. *Neuropsychopharmacology* (2010) **35**:1674–83. doi:10.1038/npp.2009.236
15. Xie P, Kranzler HR, Poling J, Stein MB, Anton RF, Farver LA, et al. Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. *Neuropsychopharmacology* (2010) **35**:1684–92. doi:10.1038/npp.2010.37
16. Appel K, Schwahn C, Mahler J, Schulz A, Spitzer C, Fenske K, et al. Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. *Neuropsychopharmacology* (2011) **36**:1982–91. doi:10.1038/npp.2011.81
17. Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. *Nat Neurosci* (2013) **16**:33–41. doi:10.1038/nn.3275
18. Bachmann AW, Sedgley TL, Jackson RV, Gibson JN, Young RM, Torpy DJ. Glucocorticoid receptor polymorphisms and post-traumatic stress disorder. *Psychoneuroendocrinology* (2005) **30**:297–306. doi:10.1016/j.psyneuen.2004.08.006
19. Segman RH, Shefi N, Goltser-Dubner T, Friedman N, Kaminski N, Shalev AY. Peripheral blood mononuclear cell gene expression profiles identify emergent post-traumatic stress disorder among trauma survivors. *Mol Psychiatry* (2005) **10**(500–513):425. doi:10.1038/sj.mp.4001676
20. de Kloet CS, Vermetten E, Bikker A, Meulman E, Geuze E, Kavelaars A, et al. Leukocyte glucocorticoid receptor expression and immunoregulation in veterans with and without post-traumatic stress disorder. *Mol Psychiatry* (2007) **12**:443–53.
21. Yehuda R, Cai G, Golier JA, Sarapas C, Galea S, Ising M, et al. Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks. *Biol Psychiatry* (2009) **66**:708–11. doi:10.1016/j.biopsych.2009.02.034
22. Boscarino JA, Erlich PM, Hoffman SN, Rukstalis M, Stewart WF. Association of FKBP5, COMT and CHRNA5 polymorphisms with PTSD among outpatients at risk for PTSD. *Psychiatry Res* (2011) **188**:173–4. doi:10.1016/j.psychres.2011.03.002
23. Mehta D, Gonik M, Klengel T, Rex-Haffner M, Menke A, Rubel J, et al. Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies. *Arch Gen Psychiatry* (2011) **68**: 901–10. doi:10.1001/archgenpsychiatry.2011.50
24. Sarapas C, Cai G, Bierer LM, Golier JA, Galea S, Ising M, et al. Genetic markers for PTSD risk and resilience among survivors of the World Trade Center attacks. *Dis Markers* (2011) **30**:101–10. doi:10.3233/DMA-2011-0764
25. van Zuiden M, Geuze E, Willemsen HL, Vermetten E, Maas M, Heijnen CJ, et al. Pre-existing high glucocorticoid receptor number predicting development of posttraumatic stress symptoms after military deployment. *Am J Psychiatry* (2011) **168**:89–96. doi:10.1176/appi.ajp.2010.10050706
26. van Zuiden M, Geuze E, Willemsen HL, Vermetten E, Maas M, Amarouchi K, et al. Glucocorticoid receptor pathway components predict posttraumatic stress disorder symptom development: a prospective study. *Biol Psychiatry* (2012) **71**:309–16. doi:10.1016/j.biopsych.2011.10.026
27. Matic G, Milutinovic DV, Nestorov J, Elakovic I, Jovanovic SM, Perisic T, et al. Lymphocyte glucocorticoid receptor expression level and hormone-binding properties differ between war trauma-exposed men with and without PTSD. *Prog Neuropsychopharmacol Biol Psychiatry* (2013) **43C**:238–45. doi:10.1016/j.pnpbp.2013.01.005
28. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. The link between childhood trauma and depression: insights from HPA axis studies in humans. *Psychoneuroendocrinology* (2008) **33**:693–710. doi:10.1016/j.psyneuen.2008.03.008
29. Bremner JD, Southwick SM, Johnson DR, Yehuda R, Charney DS. Childhood physical abuse and combat-related posttraumatic stress disorder in Vietnam veterans. *Am J Psychiatry* (1993) **150**:235–9.
30. Breslau N, Chilcoat HD, Kessler RC, Davis GC. Previous exposure to trauma and PTSD effects of subsequent trauma: results from the Detroit Area Survey of Trauma. *Am J Psychiatry* (1999) **156**:902–7.
31. Yehuda R, Halligan SL, Grossman R. Childhood trauma and risk for PTSD: relationship to intergenerational effects of trauma, parental PTSD, and cortisol excretion. *Dev Psychopathol* (2001) **13**:733–53. doi:10.1017/S0954579401003170
32. Yehuda R, Flory JD, Pratchett LC, Buxbaum J, Ising M, Holsboer E. Putative biological mechanisms for the association between early life adversity and the subsequent development of PTSD. *Psychopharmacology (Berl)* (2010) **212**:405–17. doi:10.1007/s00213-010-1969-6
33. Yehuda R. Biological factors associated with susceptibility to posttraumatic stress disorder. *Can J Psychiatry* (1999) **44**:34–9.
34. Yehuda R. Post-traumatic stress disorder. *N Engl J Med* (2002) **346**:108–14. doi:10.1056/NEJMra012941
35. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. *Am J Psychiatry* (2003) **160**:1554–65. doi:10.1176/appi.ajp.160.9.1554
36. Yehuda R. Status of glucocorticoid alterations in post-traumatic stress disorder. *Ann N Y Acad Sci* (2009) **1179**:56–69. doi:10.1111/j.1749-6632.2009.04979.x
37. van Zuiden M, Kavelaars A, Geuze E, Olff M, Heijnen CJ. Predicting PTSD: pre-existing vulnerabilities in glucocorticoid-signaling and implications for preventive interventions. *Brain Behav Immun* (2013) **30**:12–21. doi:10.1016/j.bbi.2012.08.015
38. Schmidt U, Holsboer E, Rein T. Epigenetic aspects of posttraumatic stress disorder. *Dis Markers* (2011) **30**:77–87. doi:10.1155/2011/343616
39. Perroud N, Paoloni-Giacobino A, Prada P, Olie E, Salzmann A, Nicastro R, et al. Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with a history of childhood maltreatment: a link with the severity and type of trauma. *Transl Psychiatry* (2011) **1**:e59. doi:10.1038/tp.2011.60
40. Tyrka AR, Price LH, Marsit C, Walters OC, Carpenter LL. Childhood adversity and epigenetic modulation of the leukocyte glucocorticoid receptor: preliminary findings in healthy adults. *PLoS One* (2012) **7**:e30148. doi:10.1371/journal.pone.0030148
41. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Post-traumatic stress disorder in the National Comorbidity Survey. *Arch Gen Psychiatry* (1995) **52**:1048–60. doi:10.1001/archpsyc.1995.03950240066012
42. Yehuda R, Bierer LM, Pratchett LC, Pelcovitz M. Using biological markers to inform a clinically meaningful treatment response. *Ann N Y Acad Sci* (2010) **1208**:158–63. doi:10.1111/j.1749-6632.2010.05698.x
43. First MB, Spitzer RL, Gibbon M, Williams JBW. *Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P)*. New York: Biometrics Research, New York State Psychiatric Institute (2002).
44. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, et al. The development of a Clinician-Administered PTSD Scale. *J Trauma Stress* (1995) **8**:75–90. doi:10.1002/jts.2490080106
45. Foa EB, Riggs DS, Dancu CV, Rothbaum BO. Reliability and validity of a brief instrument for assessing post-traumatic stress disorder. *J Trauma Stress* (1993) **6**:459–73. doi:10.1002/jts.2490060405
46. Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. *Child Abuse*

- Negl* (2003) **27**:169–90. doi:10.1016/S0145-2134(02)00541-0
47. King LA, King DW, Vogt DS, Knight J, Samper RE. Deployment Risk and Resilience Inventory: a collection of measures for studying deployment-related experiences of military personnel and veterans. *Mil Psychol* (2006) **18**:89–120. doi:10.1207/s15327876mp1802\_1
  48. Golier JA, Schmeidler J, Legge J, Yehuda R. Enhanced cortisol suppression to dexamethasone associated with Gulf War deployment. *Psychoneuroendocrinology* (2006) **31**:1181–9. doi:10.1016/j.psyneuen.2006.08.005
  49. Yehuda R, Bierer LM, Andrew R, Schmeidler J, Seckl JR. Enduring effects of severe developmental adversity, including nutritional deprivation, on cortisol metabolism in aging Holocaust survivors. *J Psychiatr Res* (2009) **43**:877–83. doi:10.1016/j.jpsychires.2008.12.003
  50. Yehuda R, Brand S, Yang RK. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. *Biol Psychiatry* (2006) **59**:660–3. doi:10.1016/j.biopsych.2005.08.027
  51. Yehuda R, Golier JA, Yang RK, Tischler L. Enhanced sensitivity to glucocorticoids in peripheral mononuclear leukocytes in post-traumatic stress disorder. *Biol Psychiatry* (2004) **55**:1110–6. doi:10.1016/j.biopsych.2004.02.010
  52. Lee RS, Tamashiro KL, Yang X, Purcell RH, Harvey A, Willour VL, et al. Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. *Endocrinology* (2010) **151**:4332–43. doi:10.1210/en.2010-0225
  53. Lee RS, Tamashiro KL, Yang X, Purcell RH, Huo Y, Rongione M, et al. A measure of glucocorticoid load provided by DNA methylation of Fkbp5 in mice. *Psychopharmacology (Berl)* (2011) **218**:303–12. doi:10.1007/s00213-011-2307-3
  54. Meaney MJ, Ferguson-Smith AC. Epigenetic regulation of the neural transcriptome: the meaning of the marks. *Nat Neurosci* (2010) **13**:1313–8. doi:10.1038/nn1110-1313
  55. Zhang TY, Labonte B, Wen XL, Turecki G, Meaney MJ. Epigenetic mechanisms for the early environmental regulation of hippocampal glucocorticoid receptor gene expression in rodents and humans. *Neuropsychopharmacology* (2013) **38**:111–23. doi:10.1038/npp.2012.149
  56. Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ, et al. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. *J Neurosci* (2005) **25**:11045–54. doi:10.1523/JNEUROSCI.3652-05.2005
  57. Hellstrom IC, Dhir SK, Diorio JC, Meaney MJ. Maternal licking regulates hippocampal glucocorticoid receptor transcription through a thyroid hormone-serotonin-NGFI-A signalling cascade. *Philos Trans R Soc Lond B Biol Sci* (2012) **367**:2495–510. doi:10.1098/rstb.2012.0223
  58. Unternaehrer E, Luers P, Mill J, Dempster E, Meyer AH, Staehli S, et al. Dynamic changes in DNA methylation of stress-associated genes (OXTR, BDNF) after acute psychosocial stress. *Transl Psychiatry* (2012) **2**:e150. doi:10.1038/tp.2012.77
- commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 01 June 2013; paper pending published: 19 July 2013; accepted: 11 September 2013; published online: 27 September 2013.

Citation: Yehuda R, Daskalakis NP, Desarnaud F, Makotkine I, Lehrner AL, Koch E, Flory JD, Buxbaum JD, Meaney MJ and Bierer LM (2013) Epigenetic biomarkers as predictors and correlates of symptom improvement following psychotherapy in combat veterans with PTSD. *Front. Psychiatry* **4**:118. doi: 10.3389/fpsy.2013.00118

This article was submitted to *Molecular Psychiatry*, a section of the journal *Frontiers in Psychiatry*.

Copyright © 2013 Yehuda, Daskalakis, Desarnaud, Makotkine, Lehrner, Koch, Flory, Buxbaum, Meaney and Bierer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any